HTGF et al. back in Epivios

The seed financing will help further the development of the company's cancer-testing technology through the expansion of the laboratory and the team. It will also allow the team to execute preliminary clinical validation studies. HTGF typically invests €500,000 in seed rounds.

Company
Epivios span out of Heinrich Heine University of Düsseldorf in 2011. The team, composed of the company's five founders, works on developing molecular diagnostic cancer tests for early discovery and exact diagnosis.

Their innovation is based on a new epigenetic procedure that can show changes in DNA methylation patterns. The company is based in Düsseldorf.

People
Dr Jörg Fregien worked on the deal as managing director of LSI Pre-Seed Fund. Ron Winker is investment manager at HTGF.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• High-Tech Gründerfonds
• Germany